0 169

Cited 13 times in

Successful transdermal allergen delivery and allergen-specific immunotherapy using biodegradable microneedle patches

 Ji Hye Kim  ;  Jung U Shin  ;  Seo Hyeong Kim  ;  Ji Yeon Noh  ;  Hye Ran Kim  ;  Jungsoo Lee  ;  Howard Chu  ;  Kyoung Yong Jeong  ;  Kyung Hee Park  ;  Jung Dong Kim  ;  Hong Kee Kim  ;  Do Hyeon Jeong  ;  Tai-Soon Yong  ;  Jung-Won Park  ;  Kwang Hoon Lee 
 BIOMATERIALS, Vol.150 : 38-48, 2018 
Journal Title
Issue Date
Allergens/*administration & dosage ; Animals ; Atopic/pathology/*therapy Dermatitis ; Dermatophagoides farinae/*immunology ; Immunologic/*instrumentation Desensitization ; Animal Disease Models ; Drug Delivery Systems/*instrumentation ; Female ; Hyaluronic Acid/chemistry ; Subcutaneous Injections ; Mice ; Inbred Strains Mice ; Needles ; *Transdermal Patch ; Treatment Outcome
Allergen-specific immunotherapy ; Atopic dermatitis ; Dermatophagoides farinae ; Microneedle ; NC/Nga mouse
Allergen-specific immunotherapy (SIT) is an effective treatment modality for allergic diseases such as atopic dermatitis (AD). However, frequent visits over a 3-year period as well as looming adverse events tend to discourage patient compliance. Therefore, a more convenient, effective, and safe method of SIT is needed. For several decades, use of microneedles has been promoted as an efficient and precise transdermal drug delivery method. In this study, we developed Dermatophagoides farinae (D. farinae) extract (DfE)-loaded microneedle patches, and evaluated their safety and efficacy as a novel SIT method. After 4 weeks of patch application, efficient allergen delivery and successful induction of immune response to DfE were demonstrated in mice, with no apparent adverse events. AD-induced NC/Nga mice received microneedle immunotherapy (MNIT) (10 mug), subcutaneous immunotherapy (SCIT) (10 mug), SCIT (100 mug), or placebo. Both MNIT (10 mug) and SCIT (100 mug) treatments improved clinical and histologic manifestations of AD skin lesions, altered immunoglobulin production, dampened Th2 cellular response, and boosted Treg infiltrates, without significant side effects; whereas SCIT (10 mug) or placebo subsets failed to show any effects. Based on the favorable safety and efficacy profiles demonstrated in mice by MNIT in the current study, we believe that MNIT may serve as a new SIT modality.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Dermatology (피부과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > BioMedical Science Institute (의생명과학부) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Environmental Medical Biology (환경의생물학교실) > 1. Journal Papers
5. Research Institutes (연구소) > Institute of Allergy (알레르기연구소) > 1. Journal Papers
Yonsei Authors
Chu, Howard(곡원호)
Noh, Ji Yeon(노지연)
Park, Kyung Hee(박경희) ORCID logo https://orcid.org/0000-0003-3605-5364
Shin, Jung U(신정우) ORCID logo https://orcid.org/0000-0001-5259-6879
Yong, Tai Soon(용태순) ORCID logo https://orcid.org/0000-0002-3445-0769
Lee, Kwang Hoon(이광훈)
Lee, Jungsoo(이정수)
Jeong, Kyoung Yong(정경용) ORCID logo https://orcid.org/0000-0001-9887-1426
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.